Research location
Daugavpils
Latvia
Advertisement
Research activity in Daugavpils
LatviaCureCurrent currently publishes aggregate city-level research activity for this location: 144 trials and 154 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Daugavpils
144 linked trials · page 1 of 3EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular DiseaseNCT07064473 · 2025-07-22 · 1 site observation
RECRUITING
Depemokimab as an Extended Treatment Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2)NCT06961214 · 2025-06-23 · 1 site observation
RECRUITING
A Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol Sulfate is Effective in Preventing Asthma ExacerbationsNCT06052267 · 2023-08-30 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD)NCT05878769 · 2023-06-28 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study to Evaluate Astegolimab in Participants With Chronic Obstructive Pulmonary DiseaseNCT05595642 · 2022-12-29 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Associated VTENCT05171075 · 2022-09-27 · 1 site observation
TERMINATED
Study to Evaluate Efficacy and Safety of Tezepelumab in Reducing Oral Corticosteroid Use in Adult Patients With Severe AsthmaNCT05274815 · 2022-05-17 · 2 site observations
COMPLETED
A Study Comparing Abelacimab to Apixaban in the Treatment of Cancer-associated VTENCT05171049 · 2022-05-05 · 1 site observation
TERMINATED
Study of Safety of CSJ117 in Participants With Moderate to Severe Uncontrolled AsthmaNCT04946318 · 2021-09-08 · 1 site observation
TERMINATED
A 52-week, Placebo- and Active- Controlled (Roflumilast, Daliresp® 500µg) Study to Evaluate the Efficacy and Safety of Two Doses of CHF6001 DPI (Tanimilast) as add-on to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis. (PILLAR)NCT04636814 · 2021-07-12 · 2 site observations
TERMINATED
Darolutamide in Addition to ADT Versus ADT in Metastatic Hormone-sensitive Prostate CancerNCT04736199 · 2021-02-23 · 1 site observation
COMPLETED
Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD)NCT04751487 · 2021-02-12 · 1 site observation
COMPLETED
Efficacy and Safety of Elpipodect (MK-8189) in Participants With an Acute Episode of Schizophrenia (MK-8189-008)NCT04624243 · 2020-12-15 · 1 site observation
COMPLETED
Study to Evaluate the Efficacy (Effect on Disease) and Safety of Finerenone in Participants With Heart Failure and Left Ventricular Ejection Fraction (Proportion of Blood Expelled Per Heart Stroke) Greater or Equal to 40%NCT04435626 · 2020-09-14 · 1 site observation
COMPLETED
Study of Efficacy and Safety of CSJ117 in Patients With Severe Uncontrolled AsthmaNCT04410523 · 2020-09-09 · 2 site observations
TERMINATED
Factor XI LICA to Reduce Events Such as Heart Attack and Stroke in Patients Whose Kidneys Are no Longer Able to Work as They Should and Require Treatment to Filter Wastes From the Blood: Focus is on the Safety of BAY2976217 and the Way the Body Absorbs, Distributes and Removes the Study DrugNCT04534114 · 2020-09-04 · 1 site observation
COMPLETED
A Clinical Study to Evaluate the Long-term Safety and Tolerability of an Investigational Drug in People With SchizophreniaNCT04109950 · 2019-11-20 · 1 site observation
TERMINATED
A Clinical Trial That Will Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With SchizophreniaNCT04092686 · 2019-10-14 · 1 site observation
COMPLETED
Study With Lu AF11167 for the Treatment of Negative Symptoms in Patients With SchizophreniaNCT03793712 · 2018-12-27 · 1 site observation
TERMINATED
Vortioxetine Intravenous Infusion at Initiation of Oral Treatment With Vortioxetine in Patients With DepressionNCT03766867 · 2018-12-03 · 1 site observation
COMPLETED
Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or ObesityNCT03574597 · 2018-10-24 · 1 site observation
COMPLETED
Effect of Sotagliflozin on Cardiovascular Events in Participants With Type 2 Diabetes Post Worsening Heart Failure (SOLOIST-WHF Trial)NCT03521934 · 2018-06-15 · 1 site observation
TERMINATED
Effect of Efpeglenatide on Cardiovascular OutcomesNCT03496298 · 2018-04-27 · 1 site observation
TERMINATED
Study to Investigate CSL112 in Subjects With Acute Coronary SyndromeNCT03473223 · 2018-03-21 · 1 site observation
COMPLETED
Study to Evaluate the Safety and Efficacy of Relamorelin in Participants With Diabetic Gastroparesis Study 02NCT03426345 · 2018-02-16 · 1 site observation
TERMINATED
A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis Study 04NCT03383146 · 2018-02-01 · 1 site observation
TERMINATED
A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis Study 03NCT03420781 · 2018-01-24 · 1 site observation
TERMINATED
Effect of Sotagliflozin on Cardiovascular and Renal Events in Participants With Type 2 Diabetes and Moderate Renal Impairment Who Are at Cardiovascular RiskNCT03315143 · 2017-12-19 · 1 site observation
TERMINATED
A Randomized, Double-blind Controlled Study Comparing LCZ696 to Medical Therapy for Comorbidities in HFpEF PatientsNCT03066804 · 2017-08-22 · 1 site observation
COMPLETED
Carboplatin, Etoposide, and Atezolizumab With or Without Trilaciclib (G1T28), a CDK4/6 Inhibitor, in Extensive-Stage SCLCNCT03041311 · 2017-06-29 · 1 site observation
COMPLETED
Study of Safety of QAW039 in Patients With Asthma Inadequately Controlled on Standard-of-care Asthma TreatmentNCT03052517 · 2017-03-21 · 1 site observation
TERMINATED
Randomized Placebo-controlled Trial of FCM as Treatment for Heart Failure With Iron Deficiency / and Sub-StudyNCT03037931 · 2017-03-15 · 1 site observation
COMPLETED
Study of QMF149 (150/80 µg) Compared With MF Twisthaler® (200 µg) in Patients With AsthmaNCT02892344 · 2017-01-16 · 1 site observation
COMPLETED
A Phase 2 Study to Evaluate the Cardiac and Renal Effects of Short Term Treatment With Elamipretide in Patients Hospitalized With Congestion Due to Heart FailureNCT02914665 · 2016-10-20 · 1 site observation
COMPLETED
Efficacy and Safety of BCT197 in Subjects With Acute Respiratory Exacerbations of Chronic Obstructive Pulmonary DiseaseNCT02700919 · 2016-08-01 · 1 site observation
COMPLETED
Study of ODX (Osteodex) in Metastatic Castration Resistant Prostate Cancer (CRPC)NCT02825628 · 2016-05-01 · 1 site observation
COMPLETED
Comparison of the Safety and Efficacy of HOE901-U300 With Lantus in Children and Adolescents With Type 1 Diabetes MellitusNCT02735044 · 2016-04-14 · 1 site observation
COMPLETED
A Multicenter Randomized 52 Week Treatment Double-blind, Triple Dummy Parallel Group Study to Assess the Efficacy and Safety of QMF149 Compared to Mometasone Furoate in Participants With AsthmaNCT02554786 · 2015-12-29 · 1 site observation
COMPLETED
Efficacy and Safety Study of QAW039 in Patients With Severe Asthma Inadequately Controlled With Standard of Care Asthma Treatment.NCT02555683 · 2015-12-11 · 2 site observations
COMPLETED
Study to Compare the Efficacy and Safety of QVM149 With QMF149 in Patients With AsthmaNCT02571777 · 2015-12-08 · 1 site observation
COMPLETED
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to MethotrexateNCT02629159 · 2015-12-01 · 1 site observation
ACTIVE_NOT_RECRUITING
Evaluation of the Efficacy and Safety of QVA149 (110/50 μg o.d.) vs Tiotropium (18 µg o.d.) + Salmeterol/Fluticasone Propionate FDC (50/500 µg b.i.d.) in Patients With Moderate to Severe COPDNCT02603393 · 2015-11-20 · 1 site observation
COMPLETED
A Study of Atezolizumab in Combination With Nab-Paclitaxel Compared With Placebo With Nab-Paclitaxel for Participants With Previously Untreated Metastatic Triple-Negative Breast Cancer (IMpassion130)NCT02425891 · 2015-06-23 · 1 site observation
COMPLETED
A Study to Investigate How Common Pancreatic Exocrine Insufficiency (PEI) is in Patients With Type 2 Diabetes and Also to Investigate the Uptake of a Single Dose of EPANOVA® or OMACOR® in Patients With Different Degrees of PEINCT02370537 · 2015-03-01 · 1 site observation
COMPLETED
Comparing the Efficacy of Tiotropium + Olodaterol (5/5 µg) Fixed Dose Combination (FDC) Over Tiotropium 5µg in Reducing Moderate to Severe Exacerbations in Patients With Severe to Very Severe Chronic Obstructive Pulmonary Disease.NCT02296138 · 2015-01-13 · 1 site observation
COMPLETED
Safety and Tolerability During Open-label Treatment With LCZ696 in Patients With CHF and Reduced Ejection FractionNCT02226120 · 2014-10-16 · 1 site observation
COMPLETED
Efficacy and Safety Study of Darolutamide (ODM-201) in Men With High-risk Non-metastatic Castration-resistant Prostate CancerNCT02200614 · 2014-09-12 · 1 site observation
COMPLETED
Efficacy and Safety Evaluating Study of CT-P6 in Her2 Positive Early Breast CancerNCT02162667 · 2014-06-01 · 1 site observation
COMPLETED
F17464 in Acute Schizophrenia TrialNCT02151656 · 2014-06-01 · 1 site observation
COMPLETED
Long-term Follow-up Study of GLPG0634 in Active Rheumatoid Arthritis ParticipantsNCT02065700 · 2014-02-25 · 1 site observation
COMPLETED
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.